Mitral Valve ReplacementNCT07438717
Comparative Effects of MIIT With CT In Post-MVR Surgery Patients
A study testing Moderate-Intensity Interval Training (MIIT) and Moderate-Intensity Continuous Training (MICT) in people with Mitral Valve Replacement, run by Riphah International University at 1 site in Pakistan.
Trial summary
Mitral Valve Replacement (MVR) surgery is commonly performed to treat patients with severe mitral valve diseases, such as mitral stenosis or regurgitation. Patients after mitral valve replacement surgery often experience muscular weakness ,fatigue and reduced functional capacity due to the surgical procedure and the… Read more about this study
- Who is it for?
- Ages 40 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Mitral Valve Replacement
- What is being tested?
- Moderate-Intensity Interval Training (MIIT) and Moderate-Intensity Continuous Training (MICT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 1 sitePakistan
- Study dates
- 10 Feb 2024to 5 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Both male and female age 40-60 years
- Hemodynamically stable heart rate and blood pressure
- Patients 4-8 weeks post-mitral valve replacement (MVR) surgery
- Stable medical condition for MIIT
- Able to walk independently for at least 5 minutes without assistance
- Stable pulmonary function without severe pulmonary complications (e.g., severe chronic obstructive pulmonary disease).
- No ongoing respiratory infections or severe heart failure.
Who cannot join
- Presence of unstable angina, severe heart failure (ejection fraction < 30%), or other significant cardiac arrhythmias that contraindicate exercise.
- Conditions that limit mobility or the ability to perform exercises safely (e.g., severe arthritis, recent fractures, or neuromuscular diseases).
- Patients with severe respiratory conditions (e.g., severe asthma or COPD exacerbation) that would limit participation in exercise.
- Other serious co-morbidities (e.g., uncontrolled diabetes, severe hypertension, renal failure) that may impact safe participation in exercise.
- Participation in any other structured exercise program
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Effects Of Moderate Intensity Interval Training With Continuous Training On Physical Capacity, Pulmonary Functions, Cardiac Efficiency And Quality Of Life In Post Mitral Valve Replacement Surgery Patients
Mitral Valve Replacement (MVR) surgery is commonly performed to treat patients with severe mitral valve diseases, such as mitral stenosis or regurgitation. Patients after mitral valve replacement surgery often experience muscular weakness ,fatigue and reduced functional capacity due to the surgical procedure and the time period of post-operative recovery. A structured exercise program helps rebuild strength and regain mobility, allowing patients to perform daily activities with greater ease and independence. Moderate-intensity interval training (MIIT) with continuous training is crucial for patients after mitral valve replacement (MVR) surgery, as it significantly enhances cardiopulmonary fitness. But the comparative effects of Moderate-intensity interval training (MIIT) with continuous training have not been well documented and practiced in Pakistan. The study aims to determine the comparative effects of Moderate-intensity interval training (MIIT) and moderate continuous training on physical capacity, cardiac efficiency, pulmonary function, and quality of life after mitral valve surgery. The study will be single blinded, randomized clinical trial. Based on inclusion and exclusion criteria patients were divided into two groups. The MIIT group and MICT group. The study was of 12 weeks session, 3 sessions per week (3 months). The data was analyzed through SPSS-23. Outcome measures were pulmonary function tests (spirometery), 6-Minute Walk Test (6MWT) and quality of life assessed through IPAQ. Cardiac efficiencywas measured by evaluating heart rate recovery, exercise tolerance, and cardiac output.
- Conditions
- Mitral Valve Replacement
- Being tested
- Moderate-Intensity Interval Training (MIIT), Moderate-Intensity Continuous Training (MICT)
- Keywords
- Cardiac efficiency, continuous training, mitral valve replacement, moderate-intensity interval training, physical capacity, pulmonary function, quality of life
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Moderate-Intensity Interval Training (MIIT)Other
Duration: The program lasted 12 weeks with 3 sessions per week.
Session Structure:
- Each session lasted 20-45 minutes.
- Exercise intensity was set at 50-70% of maximum heart rate (MHR).
- Intervals consisted of 1-4 minutes of moderate-intensity exercise, followed by shorter rest periods of 1-2 minutes.
Exercise Type:
- Alternating aerobic activities targeting both upper and lower body, such as treadmill and walking.
- A warm-up (5-10 minutes) and cool-down (5-10 minutes) with light stretching and low-intensity walking were included.
Moderate-Intensity Continuous Training (MICT)Other
Duration: The program lasted 12 weeks with 3 sessions per week.
Session Structure:
- Each session lasted 30-60 minutes at a steady moderate intensity.
- Exercise intensity was maintained at 50-70% of MHR without interruptions.
Exercise Type:
- Continuous aerobic activity, such as walking on a treadmill.
- A warm-up (5-10 minutes) and cool-down (5-10 minutes) were included.
| Study group | Role | What they receive |
|---|---|---|
| Group A: Moderate-Intensity Interval Training (MIIT) | Experimental | Following the consent of the participants, heart rate (HR), blood pressure, and oxygen saturation baseline measurements were taken through six minutes' walk test. The program included patient counseling on the treatment intervention and right technique, such as regular breathing patterns and avoiding breath-holding. Each session lasted 60 minutes. The targeted muscles included the biceps, triceps, and deltoids in the upper limbs, and the quadriceps, hamstrings, and calf muscles in the lower limbs, using exercises with sandbags. Exercise dosage was progressed by increasing the resistance and repetitions. Load increases were made by 5% once the participant could comfortably achieve the upper limit of the prescribed range. The protocol took total 12 weeks, with 3 sessions per week. Receives: Other: Moderate-Intensity Interval Training (MIIT) |
| Group B: Moderate-Intensity Continuous Training (MICT) | Experimental | Following the consent of the participants, heart rate (HR), blood pressure, and oxygen saturation baseline measurements were taken through six minutes' walk test. The program included patient counseling on the treatment intervention and right technique, such as regular breathing patterns and avoiding breath-holding. Each session lasted 60 minutes. The targeted muscles included the biceps, triceps, and deltoids in the upper limbs, and the quadriceps, hamstrings, and calf muscles in the lower limbs, using exercises with sandbags. Exercise dosage was progressed by increasing the resistance and repetitions. Load increases were made by 5% once the participant could comfortably achieve the upper limit of the prescribed range. The protocol took total 12 weeks, with 3 sessions per week. Receives: Other: Moderate-Intensity Continuous Training (MICT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
6MWT
The 6-Minute Walk Test (6MWT) is a functional exercise capacity test which is validated and is able to measure a patient's walking ability for six minutes considering the maximum distance covered. It reflects the capacity for aerobic activity and endurance which is why it is mostly used in cardiac rehabilitation. The test is straightforward, cheap and requires no special equipment in a doctor's office. The reliability of the 6MWT
Measured: 12 week
Digital Spirometer
Spirometry is a common and essential pulmonary function test that measures the volume of air a person can inhale and exhale, as well as how quickly they can do so. It helps in diagnosing and monitoring respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and other conditions that affect lung function. The reliability is usually good with test results reproducibility generally being above 90%. The validity is also well-defined since spirometry is rated as gold standard of measuring the lung functioning.
Measured: 12 week
VO₂ Peak
Cardiac Efficiency is defined as the heart's capability to pump blood in a manner that requires the least possible effort and still guarantees the tissues receive a good supply of oxygen. The most important indicator of cardiac efficiency is Peak Oxygen Uptake (VO₂ Peak) which comes from a cardiopulmonary exercise test (CPET) that is done under controlled conditions.
Measured: 12 weeks
IPAQ
The IPAQ (International Physical Activity Questionnaire) is the tool that is mostly adopted to evaluate quality of life via physical activity assessment. The IPAQ is made up of 7 queries which ask about the duration of the physical activities, very light to heavy, that happened in the last 7 days
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start10 Feb 2024
- Primary completion5 Jan 2025
- Study completion5 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Mitral Valve ReplacementStudies of the same condition, open and under way.
- More trials run by Riphah International UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Riphah International University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hafiza Muriam Ghani, MS-CPPT, Principal investigator, Riphah International University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07438717
- Sponsor's protocol ID
- REC/RCR&AHS/24/0385
- Status last verified
- Feb 2026
- First submitted
- 23 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hensey M, Brown RA, Lal S, Sathananthan J, Ye J, Cheung A, Blanke P, Leipsic J, Moss R, Boone R, Webb JG. Transcatheter Mitral Valve Replacement: An Update on Current Techniques, Technologies, and Future Directions. JACC Cardiovasc Interv. 2021 Mar 8;14(5):489-500. doi: 10.1016/j.jcin.2020.12.038. Epub 2021 Mar 1.
PubMed 33663778Goode D, Dhaliwal R, Mohammadi H. Transcatheter Mitral Valve Replacement: State of the Art. Cardiovasc Eng Technol. 2020 Jun;11(3):229-253. doi: 10.1007/s13239-020-00460-4. Epub 2020 Mar 4.
PubMed 32130653Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, Wijeysundera H, Sondergaard L, De Backer O, Villablanca P, Rihal C, Eleid M, Kempfert J, Unbehaun A, Erlebach M, Casselman F, Adam M, Montorfano M, Ancona M, Saia F, Ubben T, Meincke F, Napodano M, Codner P, Schofer J, Pelletier M, Cheung A, Shuvy M, Palma JH, Gaia DF, Duncan A, Hildick-Smith D, Veulemans V, Sinning JM, Arbel Y, Testa L, de Weger A, Eltchaninoff H, Hemery T, Landes U, Tchetche D, Dumonteil N, Rodes-Cabau J, Kim WK, Spargias K, Kourkoveli P, Ben-Yehuda O, Teles RC, Barbanti M, Fiorina C, Thukkani A, Mackensen GB, Jones N, Presbitero P, Petronio AS, Allali A, Champagnac D, Bleiziffer S, Rudolph T, Iadanza A, Salizzoni S, Agrifoglio M, Nombela-Franco L, Bonaros N, Kass M, Bruschi G, Amabile N, Chhatriwalla A, Messina A, Hirji SA, Andreas M, Welsh R, Schoels W, Hellig F, Windecker S, Stortecky S, Maisano F, Stone GW, Dvir D. Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement: Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry. Circulation. 2021 Jan 12;143(2):104-116. doi: 10.1161/CIRCULATIONAHA.120.049088. Epub 2020 Sep 25.
PubMed 32975133Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, Sandhu G, Salinger M, Russell H, Greenbaum A, Kodali S, George I, Dvir D, Whisenant B, Russo MJ, Pershad A, Fang K, Coylewright M, Shah P, Babaliaros V, Khan JM, Tommaso C, Saucedo J, Kar S, Makkar R, Mack M, Holmes D, Leon M, Bapat V, Thourani VH, Rihal C, O'Neill W, Feldman T. Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the United States: Data From the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv. 2020 Mar;13(3):e008425. doi: 10.1161/CIRCINTERVENTIONS.119.008425. Epub 2020 Mar 6.
PubMed 32138529Jafri SH, Hushcha P, Dorbala P, Bousquet G, Lutfy C, Klein J, Mellett L, Sonis L, Polk D, Skali H. Physical and Psychological Well-being Effects of Cardiac Rehabilitation on Patients Following Mitral Valve and Aortic Valve Procedures. J Cardiopulm Rehabil Prev. 2022 Mar 1;42(2):90-96. doi: 10.1097/HCR.0000000000000609.
PubMed 34793360Xue W, Xinlan Z, Xiaoyan Z. Effectiveness of early cardiac rehabilitation in patients with heart valve surgery: a randomized, controlled trial. J Int Med Res. 2022 Jul;50(7):3000605211044320. doi: 10.1177/03000605211044320.
PubMed 35899970Leal JM, Galliano LM, Del Vecchio FB. Effectiveness of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Hypertensive Patients: a Systematic Review and Meta-Analysis. Curr Hypertens Rep. 2020 Mar 3;22(3):26. doi: 10.1007/s11906-020-1030-z.
PubMed 32125550
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effects Of Moderate Intensity Interval Training With Continuous Training On Physical Capacity, Pulmonary Functions, Cardiac Efficiency And Quality Of Life In Post Mitral Valve Replacement Surgery Patients
- ClinicalTrials.gov ID
- NCT07438717
- Acronym / sponsor ID
- REC/RCR&AHS/24/0385
- Conditions
- Mitral Valve Replacement
- Keywords
- Cardiac efficiency, continuous training, mitral valve replacement, moderate-intensity interval training, physical capacity, pulmonary function, quality of life
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Riphah International UniversityUniversity, hospital or other
- Study start
- 10 Feb 2024 (actual)
- Primary completion
- 5 Jan 2025 (actual)
- Study completion
- 5 Jan 2025 (actual)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mitral Valve Replacement (MVR) surgery is commonly performed to treat patients with severe mitral valve diseases, such as mitral stenosis or regurgitation. Patients after mitral valve replacement surgery often experience muscular weakness ,fatigue and reduced functional capacity due to the surgical procedure and the time period of post-operative recovery. A structured exercise program helps rebuild strength and regain mobility, allowing patients to perform daily activities with greater ease and independence. Moderate-intensity interval training (MIIT) with continuous training is crucial for patients after mitral valve replacement (MVR) surgery, as it significantly enhances cardiopulmonary fitness. But the comparative effects of Moderate-intensity interval training (MIIT) with continuous training have not been well documented and practiced in Pakistan. The study aims to determine the comparative effects of Moderate-intensity interval training (MIIT) and moderate continuous training on physical capacity, cardiac efficiency, pulmonary function, and quality of life after mitral valve surgery. The study will be single blinded, randomized clinical trial. Based on inclusion and exclusion criteria patients were divided into two groups. The MIIT group and MICT group. The study was of 12 weeks session, 3 sessions per week (3 months). The data was analyzed through SPSS-23. Outcome measures were pulmonary function tests (spirometery), 6-Minute Walk Test (6MWT) and quality of life assessed through IPAQ. Cardiac efficiencywas measured by evaluating heart rate recovery, exercise tolerance, and cardiac output.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A: Moderate-Intensity Interval Training (MIIT) | Experimental | Other: Moderate-Intensity Interval Training (MIIT)Following the consent of the participants, heart rate (HR), blood pressure, and oxygen saturation baseline measurements were taken through six minutes' walk test. The program included patient counseling on the treatment intervention and right technique, such as regular breathing patterns and avoiding breath-holding. Each session lasted 60 minutes. The targeted muscles included the biceps, triceps, and deltoids in the upper limbs, and the quadriceps, hamstrings, and calf muscles in the lower limbs, using exercises with sandbags. Exercise dosage was progressed by increasing the resistance and repetitions. Load increases were made by 5% once the participant could comfortably achieve the upper limit of the prescribed range. The protocol took total 12 weeks, with 3 sessions per week. |
| Group B: Moderate-Intensity Continuous Training (MICT) | Experimental | Other: Moderate-Intensity Continuous Training (MICT)Following the consent of the participants, heart rate (HR), blood pressure, and oxygen saturation baseline measurements were taken through six minutes' walk test. The program included patient counseling on the treatment intervention and right technique, such as regular breathing patterns and avoiding breath-holding. Each session lasted 60 minutes. The targeted muscles included the biceps, triceps, and deltoids in the upper limbs, and the quadriceps, hamstrings, and calf muscles in the lower limbs, using exercises with sandbags. Exercise dosage was progressed by increasing the resistance and repetitions. Load increases were made by 5% once the participant could comfortably achieve the upper limit of the prescribed range. The protocol took total 12 weeks, with 3 sessions per week. |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Both male and female age 40-60 years
- Hemodynamically stable heart rate and blood pressure
- Patients 4-8 weeks post-mitral valve replacement (MVR) surgery
- Stable medical condition for MIIT
- Able to walk independently for at least 5 minutes without assistance
Key exclusion criteria (5 listed)
- Presence of unstable angina, severe heart failure (ejection fraction < 30%), or other significant cardiac arrhythmias that contraindicate exercise.
- Conditions that limit mobility or the ability to perform exercises safely (e.g., severe arthritis, recent fractures, or neuromuscular diseases).
- Patients with severe respiratory conditions (e.g., severe asthma or COPD exacerbation) that would limit participation in exercise.
- Other serious co-morbidities (e.g., uncontrolled diabetes, severe hypertension, renal failure) that may impact safe participation in exercise.
- Participation in any other structured exercise program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Moderate-Intensity Interval Training (MIIT)Duration: The program lasted 12 weeks with 3 sessions per week. Session Structure: * Each session lasted 20-45 minutes. * Exercise intensity was set at 50-70% of maximum heart rate (MHR). * Intervals consisted of 1-4 minutes of moderate-intensity exercise, followed by shorter rest periods of 1-2 minutes. Exercise Type: * Alternating aerobic activities targeting both upper and lower body, such as treadmill and walking. * A warm-up (5-10 minutes) and cool-down (5-10 minutes) with light stretching and low-intensity walking were included. | Other | Group A: Moderate-Intensity Interval Training (MIIT) |
| Moderate-Intensity Continuous Training (MICT)Duration: The program lasted 12 weeks with 3 sessions per week. Session Structure: * Each session lasted 30-60 minutes at a steady moderate intensity. * Exercise intensity was maintained at 50-70% of MHR without interruptions. Exercise Type: * Continuous aerobic activity, such as walking on a treadmill. * A warm-up (5-10 minutes) and cool-down (5-10 minutes) were included. | Other | Group B: Moderate-Intensity Continuous Training (MICT) |
Primary outcome
6MWT
Time frame: 12 week
The 6-Minute Walk Test (6MWT) is a functional exercise capacity test which is validated and is able to measure a patient's walking ability for six minutes considering the maximum distance covered. It reflects the capacity for aerobic activity and endurance which is why it is mostly used in cardiac rehabilitation. The test is straightforward, cheap and requires no special equipment in a doctor's office. The reliability of the 6MWT
Digital Spirometer
Time frame: 12 week
Spirometry is a common and essential pulmonary function test that measures the volume of air a person can inhale and exhale, as well as how quickly they can do so. It helps in diagnosing and monitoring respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and other conditions that affect lung function. The reliability is usually good with test results reproducibility generally being above 90%. The validity is also well-defined since spirometry is rated as gold standard of measuring the lung functioning.
VO₂ Peak
Time frame: 12 weeks
Cardiac Efficiency is defined as the heart's capability to pump blood in a manner that requires the least possible effort and still guarantees the tissues receive a good supply of oxygen. The most important indicator of cardiac efficiency is Peak Oxygen Uptake (VO₂ Peak) which comes from a cardiopulmonary exercise test (CPET) that is done under controlled conditions.
IPAQ
Time frame: 12 weeks
The IPAQ (International Physical Activity Questionnaire) is the tool that is mostly adopted to evaluate quality of life via physical activity assessment. The IPAQ is made up of 7 queries which ask about the duration of the physical activities, very light to heavy, that happened in the last 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Background: PubMed 33663778Hensey M, Brown RA, Lal S, Sathananthan J, Ye J, Cheung A, Blanke P, Leipsic J, Moss R, Boone R, Webb JG. Transcatheter Mitral Valve Replacement: An Update on Current Techniques, Technologies, and Future Directions. JACC Cardiovasc Interv. 2021 Mar 8;14(5):489-500. doi: 10.1016/j.jcin.2020.12.038. Epub 2021 Mar 1.
- Background: PubMed 32130653Goode D, Dhaliwal R, Mohammadi H. Transcatheter Mitral Valve Replacement: State of the Art. Cardiovasc Eng Technol. 2020 Jun;11(3):229-253. doi: 10.1007/s13239-020-00460-4. Epub 2020 Mar 4.
- Background: PubMed 32975133Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, Wijeysundera H, Sondergaard L, De Backer O, Villablanca P, Rihal C, Eleid M, Kempfert J, Unbehaun A, Erlebach M, Casselman F, Adam M, Montorfano M, Ancona M, Saia F, Ubben T, Meincke F, Napodano M, Codner P, Schofer J, Pelletier M, Cheung A, Shuvy M, Palma JH, Gaia DF, Duncan A, Hildick-Smith D, Veulemans V, Sinning JM, Arbel Y, Testa L, de Weger A, Eltchaninoff H, Hemery T, Landes U, Tchetche D, Dumonteil N, Rodes-Cabau J, Kim WK, Spargias K, Kourkoveli P, Ben-Yehuda O, Teles RC, Barbanti M, Fiorina C, Thukkani A, Mackensen GB, Jones N, Presbitero P, Petronio AS, Allali A, Champagnac D, Bleiziffer S, Rudolph T, Iadanza A, Salizzoni S, Agrifoglio M, Nombela-Franco L, Bonaros N, Kass M, Bruschi G, Amabile N, Chhatriwalla A, Messina A, Hirji SA, Andreas M, Welsh R, Schoels W, Hellig F, Windecker S, Stortecky S, Maisano F, Stone GW, Dvir D. Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement: Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry. Circulation. 2021 Jan 12;143(2):104-116. doi: 10.1161/CIRCULATIONAHA.120.049088. Epub 2020 Sep 25.
- Background: PubMed 32138529Guerrero M, Vemulapalli S, Xiang Q, Wang DD, Eleid M, Cabalka AK, Sandhu G, Salinger M, Russell H, Greenbaum A, Kodali S, George I, Dvir D, Whisenant B, Russo MJ, Pershad A, Fang K, Coylewright M, Shah P, Babaliaros V, Khan JM, Tommaso C, Saucedo J, Kar S, Makkar R, Mack M, Holmes D, Leon M, Bapat V, Thourani VH, Rihal C, O'Neill W, Feldman T. Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the United States: Data From the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv. 2020 Mar;13(3):e008425. doi: 10.1161/CIRCINTERVENTIONS.119.008425. Epub 2020 Mar 6.
- Background: PubMed 34793360Jafri SH, Hushcha P, Dorbala P, Bousquet G, Lutfy C, Klein J, Mellett L, Sonis L, Polk D, Skali H. Physical and Psychological Well-being Effects of Cardiac Rehabilitation on Patients Following Mitral Valve and Aortic Valve Procedures. J Cardiopulm Rehabil Prev. 2022 Mar 1;42(2):90-96. doi: 10.1097/HCR.0000000000000609.
- Background: PubMed 35899970Xue W, Xinlan Z, Xiaoyan Z. Effectiveness of early cardiac rehabilitation in patients with heart valve surgery: a randomized, controlled trial. J Int Med Res. 2022 Jul;50(7):3000605211044320. doi: 10.1177/03000605211044320.
- Background: PubMed 32125550Leal JM, Galliano LM, Del Vecchio FB. Effectiveness of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Hypertensive Patients: a Systematic Review and Meta-Analysis. Curr Hypertens Rep. 2020 Mar 3;22(3):26. doi: 10.1007/s11906-020-1030-z.
- Individual participant dataSharing planned: No
Related trials for Mitral Valve Replacement
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Mitral Valve Regurgitation
RecruitingObservational study
Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population
Mitral Valve Insufficiency
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
Active, not recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
Aortic Stenosis With Bicuspid Valve
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hafiza Muriam Ghani, MS-CPPT principal investigator
Riphah International University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Moderate-Intensity Interval Training (MIIT) and Moderate-Intensity Continuous Training (MICT) in people with Mitral Valve Replacement, run by Riphah International University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6MWT (time frame: 12 week). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07438717, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.